Zopiclone: some remarks on pharmacokinetics and pharmacodynamics

B. Schaller

Although the reported case of Kuntze et al. [1] provides some evidence that zopiclone has a favourable therapeutic index, some important data are lacking. Pharmacokinetic, pharmacodynamic and pharmacogenetic issues cannot be ignored in this context. Unfortunately, the plasma concentration of zopiclone (or urine metabolites) was not measured.

Zopiclone is a widely prescribed, non-benzodiazepine hypnotic. The duration of its pharmacological effect and the occurrence of adverse effects are mainly dependent on its biological half-life and clearance. In humans, zopiclone elimination is mainly related to its hepatic clearance as only 5% of the drug is excreted unchanged in the urine [2]. Indeed, zopiclone is extensively metabolised by the human liver into two major metabolites: N-oxidezopiclone, which retains a low pharmacological inactivity, and N-desmethylyzopiclone, which is pharmacologically inactive [3]. The enzymes involved in zopiclone metabolism have not yet been identified [2], but cytochrome P-450 isozymes may be suspected as some drug interactions in humans with cytochrome P-450 inhibitors or inducers have been reported [4–6]. The severity of beneficial or adverse drug effects may be influenced by the possible administration of such potential cytochrome P-450 inhibitors or inducers.

Secondly, zopiclone is rapidly and widely distributed in body tissues including the brain [7]. In animal experiments, the highest accumulation is in muscle, lung, liver, fat tissue and kidney [8]. From this point of view, one might suggest that an increased body mass index may have some influence on the incidence of potential adverse effects of zopiclone. In addition, the pharmacokinetics of zopiclone is altered by aging and influenced by hepatic function [7], both of which may be specific patient characteristics in the report of Kuntze et al. [1], as no exact information on hepatic function is given.

Thirdly, the lack of clinically significant adverse effects of zopiclone may be explained by its unique pharmacokinetic (rapid elimination half-life) and pharmacodynamic (low affinity and specific binding profile to various subunits of the GABA(A) receptors) profiles [9]. In order to discuss the effects of overdosage of zopiclone, the plasma level of the substance or their metabolites in the urine must be quantified. This can be done in the case of zopiclone [7, 10, 11]. For this reason, the assumption of an approximate value of a plasma level of zopiclone in the present case report may limit specific discussion from the pharmacological point of view.

In conclusion, adverse effects of zopiclone may occur under single-dose conditions or at steady-state. The pharmacodynamic consequences may or may not closely follow pharmacokinetic changes. Temporal relationship between the administration of the drug and elevated plasma concentrations may be important in determining the extent and the specificity of possible adverse effects.

Correspondence:
B. Schaller, M.D.
Max Planck Institute for Neurological Research
Gleuler Strasse 50
D-50931 Cologne
E-Mail: Bernhard.Schaller@pet.mpins-koeln.mpg.de

References
11 Bickboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther Drug Monit 2001;23:61–70.
The many reasons why you should choose SMW to publish your research

**What Swiss Medical Weekly has to offer:**

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

**Editorial Board**

- Prof. Jean-Michel Dayer, Geneva
- Prof. Peter Gehr, Berne
- Prof. André P. Perruchoud, Basel
- Prof. Andreas Schaffner, Zurich (Editor in chief)
- Prof. Werner Straub, Berne
- Prof. Ludwig von Segesser, Lausanne

**International Advisory Committee**

- Prof. K. E. Juhani Airaksinen, Turku, Finland
- Prof. Anthony Bayes de Luna, Barcelona, Spain
- Prof. Hubert E. Blum, Freiburg, Germany
- Prof. Walter E. Haefeli, Heidelberg, Germany
- Prof. Nino Kuenzli, Los Angeles, USA
- Prof. René Lutter, Amsterdam, The Netherlands
- Prof. Claude Martin, Marseille, France
- Prof. Josef Patsch, Innsbruck, Austria
- Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors: http://www.smw.ch/set_authors.html

---

**Impact factor Swiss Medical Weekly**

<table>
<thead>
<tr>
<th>Year</th>
<th>Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>0.770</td>
</tr>
<tr>
<td>1996</td>
<td>0.770</td>
</tr>
<tr>
<td>1997</td>
<td>0.890</td>
</tr>
<tr>
<td>1998</td>
<td>1.162</td>
</tr>
<tr>
<td>1999</td>
<td>1.306</td>
</tr>
<tr>
<td>2000</td>
<td>1.480</td>
</tr>
<tr>
<td>2001</td>
<td>1.537</td>
</tr>
</tbody>
</table>

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch